Niveau de preuve du suivi thérapeutique pharmacologique des inhibiteurs de tyrosine-kinase dans le traitement des leucémies myéloïdes chroniques

Rudin, 2008, Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity, J Clin Oncol, 26, 1119, 10.1200/JCO.2007.13.1128 Lu, 2006, Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer, Clin Pharmacol Ther, 80, 136, 10.1016/j.clpt.2006.04.007 Cross, 2007, Imatinib: in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia, Drugs, 67, 2645, 10.2165/00003495-200767170-00013 Druker, 2006, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia, N Engl J Med, 355, 2408, 10.1056/NEJMoa062867 Picard, 2007, Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia, Blood, 109, 3496, 10.1182/blood-2006-07-036012 Larson, 2008, Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study, Blood, 111, 4022, 10.1182/blood-2007-10-116475 Larson, 2008, Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study, Blood, 111, 4022, 10.1182/blood-2007-10-116475 Guilhot, 2008, Imatinib (IM) pharmacokinetic (PK) exposure and its correlation with clinical outcome in patients with chronicphase chronic myeloid leukemia (CML-CP) for 400 mg and 800 mg daily doses (tyrosine kinase dose optimization study [TOPS]), Blood (ASH Annual Meeting Abstracts), 112, 447 Forrest, 2009, Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels, Leuk Res, 33, 271, 10.1016/j.leukres.2008.07.015 Foryciarz, 2008, Imatinib trough plasma concentration and its correlation with clinical response in chronic phase and accelerated phase of CML, Blood (ASH Annual Meeting Abstracts), 112, 4269 Picard, 2007, Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia, Blood, 109, 3496, 10.1182/blood-2006-07-036012 Blasdel, 2007, Therapeutic drug monitoring in CML patients on imatinib, Blood, 110, 1699, 10.1182/blood-2007-03-079871 Widmer, 2008, Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability, Br J Cancer, 98, 1633, 10.1038/sj.bjc.6604355 Larson, 2008, Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study, Blood, 111, 4022, 10.1182/blood-2007-10-116475 Peng, 2004, Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients, J Clin Oncol, 22, 935, 10.1200/JCO.2004.03.050 Picard, 2007, Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia, Blood, 109, 3496, 10.1182/blood-2006-07-036012 Castaing, 2007, Quantification of eight new antidepressants and five of their active metabolites in whole blood by highperformance liquid chromatography-tandem mass spectrometry, J Anal Toxicol, 31, 334, 10.1093/jat/31.6.334 Peng, 2005, Clinical pharmacokinetics of imatinib, Clin Pharmacokinet, 44, 879, 10.2165/00003088-200544090-00001 Bolton, 2004, Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects, Cancer Chemother Pharmacol, 53, 102, 10.1007/s00280-003-0722-9 Reardon, 2005, Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme, J Clin Oncol, 23, 9359, 10.1200/JCO.2005.03.2185 Frye, 2004, Effect of St John’s wort on imatinib mesylate pharmacokinetics, Clin Pharmacol Ther, 76, 323, 10.1016/j.clpt.2004.06.007 Smith, 2004, The influence of St. John’s wort on the pharmacokinetics and protein binding of imatinib mesylate, Pharmacotherapy, 24, 1508, 10.1592/phco.24.16.1508.50958 Widmer, 2006, Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein, Br J Clin Pharmacol, 62, 97, 10.1111/j.1365-2125.2006.02719.x Petain, 2008, Population pharmacokinetics and pharmacogenetics of imatinib in children and adults, Clin Cancer Res, 14, 7102, 10.1158/1078-0432.CCR-08-0950 Menon-Andersen, 2009, Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults, Cancer Chemother Pharmacol, 63, 229, 10.1007/s00280-008-0730-x Burger, 2004, Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump, Blood, 104, 2940, 10.1182/blood-2004-04-1398 Hamada, 2003, Interaction of imatinib mesilate with human P-glycoprotein, J Pharmacol Exp Ther, 307, 824, 10.1124/jpet.103.055574 Mahon, 2003, MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models, Blood, 101, 2368, 10.1182/blood.V101.6.2368 Mahon, 2000, Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance, Blood, 96, 1070, 10.1182/blood.V96.3.1070 Thomas, 2004, Active transport of imatinib into and out of cells: implications for drug resistance, Blood, 104, 3739, 10.1182/blood-2003-12-4276 Dulucq, 2008, Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia, Blood, 112, 2024, 10.1182/blood-2008-03-147744 Crossman, 2005, hOCT 1 and resistance to imatinib, Blood, 106, 1133, 10.1182/blood-2005-02-0694 Wang, 2008, Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia, Clin Pharmacol Ther, 83, 258, 10.1038/sj.clpt.6100268 Wang, 2009, A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times, Ther Drug Monit, 31, 579, 10.1097/FTD.0b013e3181b2c8cf Tuma, 2008, Disease progression in some cancers may be due to low blood levels of targeted therapies, J Natl Cancer Inst, 100, 912, 10.1093/jnci/djn230 Le Guellec, 2009, Méthodologie pour l’évaluation du niveau de preuve du suivi thérapeutique pharmacologique, La Lettre du Pharmacologue, 23, 21